DSS (DSS) risk factors, FY2025 10-K

DSS's FY2025 10-K, filed Mar 31, 2026, lists 22 risk factors. Against the prior year's 22: 2 substantially reworded.

Risk factors listed
220 groups
New this year
0vs 22 last year
Dropped
0since the prior 10-K
Substantially reworded
2of those kept
Section length
5k wordsItem 1A

What the changes say

  • Concentration risk worsened as a single customer now accounts for 29% of consolidated revenue.
  • Secured debt repayment remains a critical risk due to history of operating losses.

What changed since the prior 10-K

Reworded

  • 49% rewritten

    A significant amount of our revenue is derived by one customers

    Customer concentration changed from two customers representing 22% and 13% of revenue to one customer representing 29% of revenue.

    Was: A significant amount of our revenue is derived by two customers

  • 34% rewritten

    We have secured indebtedness, and a potential risk exists that we may be unable to satisfy our obligations to pay interest and principal thereon when due or negotiate acceptable extensions or settlements

    The reference date for outstanding secured indebtedness was updated from December 31, 2024 to December 31, 2025.

All 22 risk factors

Headings as the filing states them, in filing order.

Other

  1. 01The value of our intangible assets and investments may not be equal to their carrying values
  2. 02We have secured indebtedness, and a potential risk exists that we may be unable to satisfy our obligations to pay interest and principal thereon when due or negotiate acceptable extensions or settlements34% rewritten
  3. 03A significant amount of our revenue is derived by one customers49% rewritten
  4. 04We may face intellectual property infringement or other claims against us, our customers or our intellectual property that could be costly to defend and result in our loss of significant rights
  5. 05Certain of our recently developed products are not yet commercially accepted and there can be no assurance that those products will be accepted, which would adversely affect our financial results
  6. 06The results of our research and development efforts are uncertain and there can be no assurance of the commercial success of our products
  7. 07The markets in which we operate are highly competitive, and we may not be able to compete effectively, especially against established industry competitors with greater market presence and financial resources
  8. 08If we are unable to respond to regulatory or industry standards effectively, our growth and development could be delayed or limited
  9. 09Breaches in security, whether cyber or physical, and other disruptions and/or our inability to prevent or respond to such breaches, could diminish our ability to generate revenues or contain costs, compromise our assets, and negatively impact our business in other ways
  10. 10Our investments in Asia are subject to unique risks and uncertainties, including tariffs and trade restrictions
  11. 11Future growth in our business could make it difficult to manage our resources
  12. 12If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to remain competitive, continue to expand our technology or pursue growth
  13. 13We do not intend to pay cash dividends
  14. 14We may seek to develop additional new inventions and intellectual property, which would take time and would be costly. Moreover, the failure to obtain or maintain intellectual property rights for such inventions would lead to the loss of our investments in such activities
  15. 15Changes in the laws and regulations to which we are subject may increase our costs
  16. 16Declines in general economic conditions or acts of war and terrorism may adversely impact our business
  17. 17Our common stock is currently listed for trading on the NYSE American LLC Exchange (“NYSE American”), and the continued listing of our common stock on the NYSE American is subject to our compliance with a number of listing standards
  18. 18If we are delisted from the NYSE American, your ability to sell your shares of our common stock may be limited by the penny stock restrictions, which could further limit the marketability of your shares
  19. 19If our common stock is not listed on a national securities exchange, compliance with applicable state securities laws may be required for certain offers, transfers and sales of the shares of our common stock
  20. 20If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline
  21. 21Because certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder approval
  22. 22Additional financing or future equity issuances may result in future dilution to our shareholders

Other DSS 10-Ks

  • FY2024 10-K risk factors
    22 risks

    DSS relies heavily on two customers and $18.9 million in intangible assets, mainly Impact BioMedical.

    Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.